Balyasny Asset Management LLC Corvus Pharmaceuticals, Inc. Transaction History
Balyasny Asset Management LLC
- $63.6 Billion
- Q4 2024
A detailed history of Balyasny Asset Management LLC transactions in Corvus Pharmaceuticals, Inc. stock. As of the latest transaction made, Balyasny Asset Management LLC holds 48,335 shares of CRVS stock, worth $205,907. This represents 0.0% of its overall portfolio holdings.
Number of Shares
48,335Holding current value
$205,907% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding CRVS
# of Institutions
102Shares Held
38.1MCall Options Held
2.75MPut Options Held
1.17M-
Orbimed Advisors LLC San Diego, CA6.94MShares$29.6 Million0.98% of portfolio
-
Samlyn Capital, LLC New York, NY6.67MShares$28.4 Million0.56% of portfolio
-
Adams Street Partners LLC Chicago, IL3.28MShares$14 Million18.22% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct3.03MShares$12.9 Million0.04% of portfolio
-
Rtw Investments, LP New York, NY2.68MShares$11.4 Million0.23% of portfolio
About Corvus Pharmaceuticals, Inc.
- Ticker CRVS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,553,500
- Market Cap $198M
- Description
- Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The compan...